HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S-P settles Clarinex suit

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough agrees to pay $165 million to settle a class-action lawsuit that news reports indicate is related to the firm's alleged failure to disclose information about the FDA review of the prescription allergy product. In a Feb. 27 posting on its Web site, Schering says the settlement was preliminarily approved by a federal court in Newark, N.J., and a final approval hearing is slated for June 1. The firm's online statement does not identify the subject of the settlement, but states the amount. Investors involved in the litigation said the company failed to disclose manufacturing problems that blocked the approval of Clarinex and led to a 2002 FDA consent decree against Schering (1"The Tan Sheet" Jan. 10, 2005, p. 5). Clarinex (desloratadine) has been mentioned as a potential OTC switch candidate (2"The Tan Sheet" Feb. 5, 2007, p. 4)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

RS136449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel